Mass. Movers

Dyax climbs as analyst raises price target


Burlington-based Dyax Corp. got a higher price target from Needham & Co. analyst Serge Belanger, who reiterated a “buy” rating. The new price target is $13, up from $7.50, thanks to the experimental drug DX2930. “The DYAX story . . . now centers on DX2930, the company’s antibody under development for prophylactic HAE treatment,” Belanger said. He expects favorable study data soon. The drug is for hereditary angioedema, a rare acute inflammatory condition with severe swelling of the extremities, gastrointestinal tract, genitalia, and larynx.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
We hope you've enjoyed your free articles.
Continue reading by subscribing to for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of